Patheon is expanding its manufacturing facility in France to enable it to bring to Europe the same services that it offers from its plants in North America
Contract drug manufacturer Patheon is expanding its manufacturing facility in France to enable it to bring to Europe the same services that it offers from its plants in North America.
The facility at Bourgoin-Jallieu, outside Lyon, will be able to offer a full range of solid dose Phase III and commercial supplies as part of its Pharmaceutical Development Services (PDS) business once the expansion is completed by the end of this year.
"With this expansion we will offer the same services in Europe by the end of 2010," said Wes Wheeler, Patheon's ceo and president.
"The investment reinforces our commitment to provide our customers with a full range of product development services - from pre-clinical through late phase stages, on to commercialisation."
The company said the new facility will supply late-phase clinical trial tablet and capsule products, and will be capable of handling batch sizes up to 120kg. It will consist of a new pilot plant and equipment designed to contain high potency products. Process trains will be scalable to commercial lines, offering clients the ability to produce Phase III and commercial product in the same location.